Patients' role in reporting adverse drug reactions

Expert Opinion on Drug Safety

Volumn 3, Issue 4, 2004, Pages 363-368

  van Grootheest, Kees ^a   de Jong van den Berg, Lolkje ^b  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Adverse drug reaction (ADR); Consumer; Patients; Pharmacovigilance; Spontaneous reporting system (SRS)

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHLORAMPHENICOL; DIETHYLSTILBESTROL; HYPNOTIC AGENT; NON PRESCRIPTION DRUG; ORAL CONTRACEPTIVE AGENT; THALIDOMIDE;

APLASTIC ANEMIA; CONGENITAL MALFORMATION; CONSUMER; CORRELATION ANALYSIS; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EXPERIENCE; HUMAN; INTERNET; MEDICAL INFORMATION SYSTEM; MEDICAL LITERATURE; PATIENT ATTITUDE; PATIENT RIGHT; PUBLIC HEALTH; QUALITY CONTROL; REVIEW; RISK REDUCTION; SELF REPORT; THROMBOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; PATIENT PARTICIPATION; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 3543114278     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.4.363     Document Type: Review

References (30)

1. BEIJER HJ, DE BLAEY CJ: Hospitalisations caused by adverse drug reactions (ADRs): a meta-analysis of observational studies. Pharm. World Sci. (2002) 24:46-54.
2. WALLERSTEIN RO, CONDIT PK, KASPER CK, BROWN JW, MORRISON FR: Statewide study of chloramphenicol therapy and fatal aplastic anemia. J. Am. Med. Assoc. (1969) 208:2045.
3. MEYLER L: Side Effects of Drugs. Excerpta Medica Foundation, Amsterdam (1952).
4. LENZ W. Malformations caused by drugs in pregnancy. Am. J. Dis. Child. (1966) 112:99-106.
5. LINDQUIST AM: Seeing and Observing in International Pharmacovigilance. Academic Thesis. Katholieke Universiteit Nijmegen, Nijmegen (2003).
6. BARRY CA, BRADLEY CP, BRITTEN N, STEVENSON FA, BARBER N: Patients' unvoiced agendas in general practice consultations: qualitative study. Br. Med. J. (2000) 320:1246-1250.
7. DE JONG-VAN DEN BERG LT, TOBI H, BIJKER B, VAN DEN BERG PB: Influence of the third generation pill controversy on prescriptions for oral contraceptives among first time users: population based study. Br. Med. J. (2003) 326:254.
8. MEDAWAR C, HERXHEIMER A, BELL A, SHELLEY J: Paroxetine, Panorama and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing drug surveillance. Int. J. Risk Saf. Med. (2002) 13:161-169.
9. HERXHEIMER A, MCPHERSON A, MILLER R, SHEPPERD S, YAPHE J, ZIEBRAND S: Database of patient's experiences (DIPEx): a multi-media approach to sharing experiences and information. Lancet (2000) 355:1540-1543.
10. VAN GROOTHEEST AC: Improving Pharmacovigilance and the Role of the Pharmacists. Academic Thesis. Rijksuniversiteit Groningen, Groningen (2003).
11. VAN GROOTHEEST AC, EDWARDS IR: Labelling and 'Dear Doctor' letters: are the noncommittal? Drug Saf. (2002) 25:1051-1055.
12. SELIGMAN PJ: 'Dear Doctor...' - evaluating the impact of risk communication efforts. Pharmacoepidemiol. Drug Saf. (2003) 12:291-294.
13. KANJANARAT P, WINTERSTEIN AG, JOHNS TW, HATTON RC, GONZALEZ-ROTHI R, SEGAL R: Nature of preventable adverse drug events in hospital: a literature review. Am. J. Health Syst. Pharm. (2003) 60:1750-1759.
14. HALLAS J, HARVALD B, GRAM LF et al.: Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J. Intern. Med. (1990) 228:83-90.
15. STROM BL (Ed.): Pharmaroepidemiology (3rd edn). Wiley, Chichester (2000).
16. MEYBOOM RH: Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. (1997) 16:374-389.
17. VAN GROOTHEEST AC, OLSSON S, COUPER M, DE JONG VAN DEN BERG LT: The role of pharmacists in reporting adverse drug reactions in international perspective. Pharmacoepidemiol. Drug Saf. (2004). In Press.
18. MORRISON-GRIFFITHS S, WALLEY TJ, PARK BK, BRECKENRIDGE AM, PIRMOHAMED M: Reporting of adverse drug reactions by nurses. Lancet (2003) 361:1347-1348.
19. EDWARDS IR: Spontaneous reporting - of what? Clinical concerns about drugs. Br. J. Clin. Pharmacol. (1999) 48:138-141.
20. NO AUTHORS LISTED: Improving ADR reporting. Lancet (2002) 360:1435.
21. VAN GROOTHEEST K, DE GRAAF L, DE JONG-VAN DEN BERG LT: Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf. (2003) 26:211-217.
22. EGBERTS TC, SMULDERS M, DE KONING FH, MEYBOOM RH, LEUFKENS HG: Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. Br. Med. J. (1996) 313:530-531.
23. GURWITZ JH, ANDRADE SE: Risk management in therapeutics: when the patient becomes the last line of defense. Pharmacoepidemiol. Drug Saf. (2002) 11:637-639.
24. HUGHES CM: Monitoring self-medication. Expert Opin. Drug Saf. (2003) 2:1-5.
25. WORLD HEALTH ORGANIZATION: Direct reporting by consumers - First International Conference. WHO Pharmaceutical Newsletter (2000) 3:12-13.
26. SOLOVITCH BL, FISHER S, BRYAND SG et al.: How well can patients discriminate drug-related side effects from extraneous new symptoms? Psychopharmacol. Bull. (1987) 23:189-198.
27. MITCHELL AS, HENRY DA, SANSON-FISCHER R et al.: Patients as a direct source of information of adverse drug reactions. Br. Med. J. (1988) 297:891-893.
28. VAN GROOTHEEST AC, VAN PUIJENBROEK EP, DE JONG-VAN DEN BERG LT: Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf. (2002) 11:205-210.
29. MAYOR S: Helpline for patients to report adverse reactions is piloted in England. Br. Med. J. (2003) 326:951.
30. FLEURANCEAU-MOREL P: How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers. Pharmacoepidemiol. Drug Saf. (2002) 11:37-44.